It's been a rocky few months for those stocks as sales of Covid shots and treatments plummet in the U.S.: Shares of all four companies are down more than 20% for the year. But Wall Street's enthusiasm for Covid vaccine makers is getting a fresh boost with the upcoming launch of brand-new shots this fall and the emergence of new variants of the virus.
Feeling out of the loop? We'll catch you up on the Chicago news you need to know. Sign up for the weeklyThat includes EG.5, also known as"Eris," which is now the dominant Covid strain in the U.S. Health experts told CNBC that Eris may be slightly better at evading immunity from previous vaccinations and infections, but the variant isn't expected to be more severe.
Moderna, Pfizer and Novavax have also said that their new shots, which are designed to target a related omicron subvariant called XBB.1.5, should provide protection against Eris. But it's unclear how well the new shots will protect against a new omicron strain of the virus calledMoney Report